Denison Mines announces $250 million convertible notes offering
Margaret Horn, Chief Operating Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), sold 3,510 shares of common stock on June 16, 2025. The shares were sold at prices ranging from $39.6017 to $39.8291, for a total value of $139,803. The transaction occurred near InvestingPro’s Fair Value estimate for the $7.4 billion biotech company, with analysts setting price targets between $57 and $88.
Following the transaction, Horn directly owns 150,675 shares, which includes 652 shares acquired under the company’s Employee Stock Purchase Plan on May 31, 2025, and 79,776 restricted stock units.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax obligations related to the vesting of restricted stock units.
In other recent news, Revolution Medicines has announced a strong cash position following its Q1 2025 earnings call, with $2.1 billion in cash, intended to fund operations into the second half of 2027. Despite a net loss of $213.4 million, the company remains focused on advancing its cancer treatment pipeline. Revolution Medicines has initiated a Phase 3 clinical trial for its drug daraxonrasib, targeting non-small cell lung cancer (NSCLC) with specific RAS mutations. This trial, named RASolve 301, aims to enroll approximately 420 patients globally. Meanwhile, Oppenheimer has maintained an Outperform rating on Revolution stock, citing the company’s focus on clinical programs as a positive indicator. However, H.C. Wainwright has adjusted the stock’s price target to $72.00, while maintaining a Buy rating, following recent clinical data presentations. These developments reflect Revolution Medicines’ ongoing efforts to establish its RAS inhibitors as leading therapies in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.